MARKET

ADMS

ADMS

Adamas Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.880
+0.020
+0.41%
After Hours: 4.880 0 0.00% 16:00 09/24 EDT
OPEN
4.810
PREV CLOSE
4.860
HIGH
4.960
LOW
4.768
VOLUME
72.71K
TURNOVER
--
52 WEEK HIGH
9.15
52 WEEK LOW
2.960
MARKET CAP
222.51M
P/E (TTM)
-2.8920
1D
5D
1M
3M
1Y
5Y
Adamas Announces GOCOVRI Presentations at the Upcoming International Parkinson and Movement Disorder Society's (MDS) Congress
Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced five posters will be presented at the International Parki...
Business Wire · 09/16 13:15
Adamas Announces New Employment Inducement Grants
Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company's board of directors granted seven new employees restricted stock units to acquire 94,750 shares of the company's common stock. The restricted stock ...
Business Wire · 09/10 21:00
Looking Into Adamas Pharmaceuticals's Return On Capital Employed
According to data from Benzinga Pro, during Q2, Adamas Pharmaceuticals's (NASDAQ:ADMS) reported sales totaled $21.97 million. Despite a 3.88% increase in earnings, the company posted a loss of $9.15 million.
Benzinga · 09/10 15:53
Adamas to Present at Upcoming September Investor Conferences
EMERYVILLE, Calif., August 30, 2021--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced that management will...
Business Wire · 08/30 20:11
Adamas Announces New Employment Inducement Grant
EMERYVILLE, Calif., August 13, 2021--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company’s board of directors granted three new employees restricted stock units to acquire 38,500 shares of the company’...
Business Wire · 08/13 20:16
Adamas Pharmaceuticals (ADMS) Reports Q2 Loss, Lags Revenue Estimates
Adamas (ADMS) delivered earnings and revenue surprises of 0.00% and -1.21%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 08/09 21:15
Adamas Pharmaceuticals Q2 EPS $(0.27) Beats $(0.29) Estimate, Sales $22.00M Beat $21.95M Estimate
Adamas Pharmaceuticals (NASDAQ:ADMS) reported quarterly losses of $(0.27) per share which beat the analyst consensus estimate of $(0.29) by 6.9 percent. This is a 27.03 percent increase over losses of $(0.37) per share
Benzinga · 08/09 20:14
-- Earnings Flash (ADMS) ADAMAS PHARMACEUTICALS Reports Q2 Revenue $22M, vs. Street Est of $21.8M
MT Newswires · 08/09 16:13
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ADMS. Analyze the recent business situations of Adamas Pharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 9 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ADMS stock price target is 8.79 with a high estimate of 14.00 and a low estimate of 3.000.
EPS
Institutional Holdings
Institutions: 123
Institutional Holdings: 32.77M
% Owned: 71.87%
Shares Outstanding: 45.60M
TypeInstitutionsShares
Increased
24
1.74M
New
9
2.93M
Decreased
14
1.42M
Sold Out
14
3.30M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.13%
Pharmaceuticals & Medical Research
-1.02%
Key Executives
Chairman/Lead Director/Independent Director
David Mahoney
Chief Executive Officer/Director
Neil McFarlane
Chief Financial Officer/Chief Accounting Officer
Christopher Prentiss
Other
Adrian Quartel
Other
Vijay Shreedhar
Independent Director
Michael Bigham
Independent Director
Martha Demski
Independent Director
William Ericson
Independent Director
John MacPhee
Independent Director
Spyridon Papapetropoulos
Independent Director
Anna Richo
No Data
About ADMS
Adamas Pharmaceuticals, Inc. is a commercial-stage pharmaceutical company. The Company is engaged in drug discovery, development and commercialization to deliver medicines for patients, caregivers, and society. The Company’s portfolio product GOCOVRI (amantadine) extended release capsules is used for the treatment of dyskinesia in patients with Parkinson’s disease. Its OSMOLEX ER (amantadine) extended-release tablets is used for the treatment for Parkinson’s disease and drug-induced extrapyramidal reactions in adult patients. Its ADS-5102 is in development for the treatment of walking impairment in patients with multiple sclerosis (MSW). Its product candidate ADS-4101 (lacosamide) modified release capsules is in development for the treatment of partial onset seizures in patients with epilepsy. Its Namzaric (memantine hydrochloride extended release and donepezil hydrochloride) capsules are used for the treatment of dementia of an Alzheimer’s type.

Webull offers kinds of Adamas Pharmaceuticals Inc stock information, including NASDAQ:ADMS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ADMS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ADMS stock methods without spending real money on the virtual paper trading platform.